Search clinical trials for: Lorcaserin Hydrochloride

Total 7357 results

Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions
Eisai Inc.

Completed

A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age

Obesity

United States
Eisai Inc.

Terminated

Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years

Obesity

United States
National Institute on Drug Abuse (NIDA)

Completed

Lorcaserin in the Treatment of Cocaine Use Disorder

Cocaine-Related Disorders

United States
Arena Pharmaceuticals

Completed

A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation

Smoking Cessation

United States
Eisai Inc.
Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization

Completed

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors (CAMELLIA-TIMI)

Obesity | Cardiovascular Disease | Overweight | Type 2 Diabetes | High Cardiovascular Risk

United States, Canada, Poland, Australia, Mexico, New Zealand, Bahamas, Chile
Eisai Inc.

Completed

Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects

Obesity

United States
Eisai Inc.

Completed

Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Eisai Inc.

Available

Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies

Epilepsies, Myoclonic | Drug Resistant Epilepsy
Eisai Inc.

Completed

Abuse Potential of Single Doses of Lorcaserin in Healthy Recreational Polydrug Users

Healthy | Drug Abuse

Canada
Eisai Inc.

Recruiting

A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome (MOMENTUM 1)

Epilepsies, Myoclonic

United States, Canada
Johns Hopkins University

Terminated

Evaluating Muscle Weakness Improvement With Lorcaserin in ICU (EMILI)

Sepsis | Muscle Weakness

United States
Scripps Whittier Diabetes Institute
Eisai Inc.

Completed

Lorcaserin: Real World Experience in an Insurance-Based Weight Management Clinic

Obesity | Overweight | Weight Loss

United States
Eisai Inc.

Completed

Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age

Pharmacokinetics in Obese Adolescents

United States
Eisai Inc.

Completed

Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment

Renal Impairment

United States
Eisai Inc.

Completed

Pharmacokinetic Properties of Lorcaserin in the Fed and Fasted State

Obesity

United States
University of Pennsylvania
Eisai Inc.

Completed

Lifestyle Modification and Lorcaserin for Weight Loss Maintenance

Obesity

United States
Eisai Inc.

Completed

A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants

Healthy Participants

United States
Columbia University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); New...

Terminated

Predictors of Lorcaserin-Induced Weight Loss

Overweight and Obesity

United States
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Completed

Effect of Lorcaserin on Cannabis Withdrawal and Self-administration

Cannabis Use

United States
Eisai Inc.

Completed

To Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake (TULIP)

Obesity

United States
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Terminated

Lorcaserin for Cannabis Use Disorder

Cannabis Use Disorder

United States
New York State Psychiatric Institute

Completed

Use of a Mobile Health Sensor in an Open Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder

Cannabis Use Disorder

United States
Eisai Inc.

Completed

BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management

Obesity

United States
Midwest Biomedical Research Foundation

Unknown

Lorcaserin Intra Venous Cocaine Effects (LIVE)

Cocaine Use Disorders

United States
Kanion & Huawe Medicine Co.,Ltd

Terminated

Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Obese Patients

Obesity

China
Eisai Inc.

Completed

BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management

Obesity

United States
Eisai Inc.

Completed

BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus

Obesity

United States
The Mind Research Network

Terminated

Mechanisms of Lorcaserin for Smoking Cessation

Smoking Cessation | Tobacco Use Disorder

United States
Eisai Inc.

Completed

A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults

Chronic Weight Management

United States
Beth Israel Deaconess Medical Center

Active, not recruiting

Lorcaserin in Obesity: Identification of CNS Targets Using fMRI

Obesity | Weight Loss

United States
Virginia Commonwealth University
National Institute on Drug Abuse (NIDA)

Completed

Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder

Opioid-Related Disorders | Opioid Dependence | Opioid Use | Opioid Abuse

United States
Virginia Commonwealth University
National Institute on Drug Abuse (NIDA)

Terminated

Phase I Functional Magnetic Resonance Imaging (fMRI) Pharmacodynamic Studies of Compounds for Opioid Use Disorder and Cocaine Use Disorder

Opioid-Related Disorders | Cocaine-Related Disorders

United States
Mayo Clinic

Completed

Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management

Overweight | Obese

United States
Mclean Hospital

Active, not recruiting

Rebalancing the Serotonergic System in Cocaine Dependence

Cocaine Dependence

United States
New York State Psychiatric Institute

Completed

Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder

Opioid-use Disorder

United States
Southern California Institute for Research and...

Unknown

Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study

Weight Gain

United States
Duke University
National Institute on Drug Abuse (NIDA)

Completed

Combination Nicotine Patch / Lorcaserin for Smoking Cessation (LorNic)

Nicotine Dependence

United States
The Mind Research Network

Terminated

Laboratory Screening of Lorcaserin for Alcohol Use Disorder

Tobacco Smoking | Alcohol Use Disorder

United States
University of North Carolina, Chapel Hill
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Columbia...

Terminated

MEtformin and Lorcaserin for WeighT Loss in Schizophrenia (MELT)

Overweight | Schizophrenia | Schizoaffective Disorder

United States
University Hospital, Strasbourg, France

Recruiting

Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory Neuropathies (TINISS)

Primary Sjögren's Syndrome Painful Sensory Neuropathies

France
Southeastern Regional Medical Center

Unknown

Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

Chemotherapy-Induced Peripheral Neuropathy

United States
Mayo Clinic

Completed

Lorcaserin for Preventing Weight Gain Among Smokers

Tobacco Use Disorder | Weight Gain

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Suspended

Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
Mayo Clinic
National Institute on Drug Abuse (NIDA)

Terminated

Addressing Post Cessation Weight Gain

Smoking Cessation | Obesity

United States
Neelesh Sharma MD PhD

Completed

Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Xijing Hospital of Digestive Diseases

Completed

A Research of Berberine Hydrochloride to Prevent Colorectal Adenomas in Patients With Previous Colorectal Cancer

Colorectal Adenomas

China
Xijing Hospital of Digestive Diseases

Completed

Primary Chemoprevention of Familial Adenomatous Polyposis With Berberine Hydrochloride

Colorectal Adenomas

China
Shenyang Sunshine Pharmaceutical Co., LTD.

Unknown

A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet

Uremic Pruritus

China
Galderma R&D

Completed

Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma

Basal Cell Carcinoma

Australia

Search clinical trials for: Lorcaserin Hydrochloride

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations